Boston Scientific Corporation (BSX)

FairStock Score: 66/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Boston Scientific as a medical-device operator with real scale—59,000 employees and devices used in interventional specialties—but I want the numbers to carry the argument. The filed record shows momentum: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $5.4B, net income $905.0M, and diluted EPS $0.61, versus revenue $5.1B, net income $795.0M, and EPS $0.53 in fiscal Q2 2025. For fiscal 2025, revenue was $20.1B and net income $2.9B, up from $16.7B and $1.8B in fiscal 2024. FairStock classifies it as a FAST GROWER, citing 29.1% annual profit growth over four years and 14.0% revenue growth. Financial health is acceptable rather than fortress-like: debt-to-equity is 0.50, Piotroski 6/9, Altman Z 2.48, ROE 15.34%, but ROCE only 6.19%. Free cash flow is $1.8B TTM, a 2.7% FCF yield. At the $45.58 close on 2026-10-26, FairStock calculates P/E 18.45, P/B 2.65, EV/EBITDA 13.89, and PEG 1.34. Against Graham Number of $30.94, the price is about 47.67% above that arithmetic, so there is no margin of safety. I see quality and growth, but not a Graham bargain. The moat may come from clinical switching costs and regulation, yet the figures do not prove it. I would require better ROCE and FCF yield before calling the price attractive.

In plain English: Boston Scientific makes medical devices for heart and other internal procedures. The business looks reasonably strong: sales and profit have grown, cash flow is positive, and debt is moderate. At $45.58, the stock does not look cheap based on the company’s reported numbers; it looks fair to somewhat expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer